作者
Sandra P D’Angelo, James Larkin, Jeffrey A Sosman, Celeste Lebbé, Benjamin Brady, Bart Neyns, Henrik Schmidt, Jessica C Hassel, F Stephen Hodi, Paul Lorigan, Kerry J Savage, Wilson H Miller Jr, Peter Mohr, Ivan Marquez-Rodas, Julie Charles, Martin Kaatz, Mario Sznol, Jeffrey S Weber, Alexander N Shoushtari, Mary Ruisi, Joel Jiang, Jedd D Wolchok
发表日期
2017/1/10
期刊
Journal of Clinical Oncology
卷号
35
期号
2
页码范围
226-235
出版商
American Society of Clinical Oncology
简介
Purpose
Mucosal melanoma is an aggressive malignancy with a poor response to conventional therapies. The efficacy and safety of nivolumab (a programmed death-1 checkpoint inhibitor), alone or combined with ipilimumab (a cytotoxic T-lymphocyte antigen-4 checkpoint inhibitor), have not been reported in this rare melanoma subtype.
Patients and Methods
Data were pooled from 889 patients who received nivolumab monotherapy in clinical studies, including phase III trials; 86 (10%) had mucosal melanoma and 665 (75%) had cutaneous melanoma. Data were also pooled for patients who received nivolumab combined with ipilimumab (n = 35, mucosal melanoma; n = 326, cutaneous melanoma).
Results
Among patients who received nivolumab monotherapy, median progression-free survival was 3.0 months (95% CI, 2.2 to 5.4 months) and 6.2 months (95% CI, 5.1 to 7.5 months) for mucosal and cutaneous …
学术搜索中的文章
SP D'Angelo, J Larkin, JA Sosman, C Lebbé, B Brady… - Journal of Clinical Oncology, 2017